Moderna
Pioneering biotechnology company that developed the mRNA technology platform, revolutionizing vaccine and therapeutic development, including the highly successful COVID-19 vaccine.
Notes
Moderna is a biotechnology pioneer that developed and commercialized mRNA technology for therapeutics and vaccines. The company's mRNA platform enables the rapid design and production of vaccines and therapeutics by instructing cells to produce specific proteins.
Founded in 2010 as a Flagship Pioneering portfolio company, Moderna achieved global recognition with the development of mRNA-1273 (Spikevax), one of the first COVID-19 vaccines authorized worldwide. The company is now expanding its mRNA platform across multiple therapeutic areas including infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.
Team
- Stéphane Bancel - Chief Executive Officer
- LinkedIn: linkedin.com/in/stephanebancel
- Stephen Hoge, M.D. - President
- Jamey Mock - Chief Financial Officer
- Paul Burton, M.D., Ph.D. - Chief Medical Officer
Additional Research Findings
- Founded in 2010
- Headquarters in Cambridge, Massachusetts
- Listed on NASDAQ (MRNA)
- Flagship Pioneering portfolio company
- mRNA-1273 (Spikevax) COVID-19 vaccine
- Over $20 billion in COVID vaccine revenues
- Expanding into oncology, rare diseases, and personalized cancer vaccines
- mRNA technology platform with broad applications
- One of the most valuable biotech companies globally
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Flagship Pioneering | Cambridge, USA | biotech-focused | seedseries-a+3 | 1 |